Contribution of locus coeruleus activity patterns on TAU deposition in alzheimer's disease
Active Project Grant Awarded Last action
- Award ID
- R21AG081681
- Recipient
-
The General Hospital Corporation UEI FLJ7DQKLL226
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,566,000
Award facts
- Assistance listing
- 93.866 Aging Research
- Completion date 88% complete
- Originally
- Place of performance
- Boston, MA 02114, USA
Award details come from USAspending.gov.
Description
- Abstract
- Alzheimer's disease (ad)'s neuropathologic hallmarks are the accumulation of amyloid-beta (ASS) and TAU proteins. Thus far, therapeutic efforts have been mainly focused on ASS and showed limited success, underscoring the need for alternative approaches of intervention, particularly those that can target mechanisms related to the initial propagation of pathology. The locus coeruleus (LC) has been identified as one of the earliest regions affected by TAU: by the age of 40, 80% of individuals exhibit TAU aggregation in the LC, and by the age of 50, 50% of individuals exhibit TAU aggregation in the entorhinal cortex (EC), suggesting TAU progression from the LC to the medial temporal lobe (MTL). However, the mechanism of TAU propagation is yet unknown. Accumulated evidence from animal research suggests that pathologic TAU propagates via axons and cell-to-cell transmission and that synaptic and neuronal activity levels facilitate this process. Furthermore, a recent study using a RAT model of pretangle TAU in LC neurons and optogenetic stimulation suggested that novelty-like phasic LC activation protects against the deleterious changes linked to pretangle TAU. In contrast, stress-associated tonic LC activation worsens LC neuronal health and promotes depressive behaviors that have been associated with TAU accumulation in the EC. Our own preliminary data shows that lower novelty-related LC activation is related to higher TAU deposition in the EC and steeper memory decline in cognitively healthy older individuals. This evidence forms the scientific premise for the hypothesis that phasic versus tonic resting-state LC activity may be associated with mechanisms of TAU propagation and ultimately predict cognitive decline. The goal of this proposal is to examine the relationship between the balance between phasic versus tonic LC activity detected in resting- state fmri data and TAU deposition in the EC and the MTL across all stages of the ad continuum and cognitive decline. To achieve this, we will resolve two methodological barriers: (II) accounting for the hemodynamic blurring in resting-state fmri using deconvolution in terms of an optimally defined region- and subject-specific hemodynamic response function, and (II) using novel event-detection techniques for the detection of periods of phasic and tonic activity in the deconvoluted LC. Our methodology for quantifying the balance between phasic versus tonic LC activity will be fine-tuned and validated using simultaneous LC bold-fmri, fiber photometry calcium imaging, and pupil dilation data collected from awake rodents during resting-experimental conditions. Combining these state-of-the-art novel methods with TAU-, ASS-pet, and longitudinal cognitive data from the harvard aging brain study and the alzheimer disease neuroimaging initiative, will allow US to examine the following aims: aim 1) to investigate the associations between cross-sectional patterns of LC activity with age, SEX, TAU, and beta-amyloid pathology among individuals of varying biomarker levels, aim 2) to relate LC activation patterns to cognitive decline as a function of ad pathology. Together, these aims contribute to our understanding of the mechanistic underpinnings of initial TAU propagation and its relevance for cognition.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $16,700 | |
| Amendment | $150,300 | |
| Amendment | $150,300 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $249,550 | |
| Amendment | $249,550 | |
| Amendment | $249,550 | |
| Amendment | $249,550 | |
| Original award | $250,500 |
Show all 13
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Universite De Geneve | $32,400 | |
| Ecole Polytechnique Federale De Lausanne, Epfl | $32,400 |
Quick answers
Who received award R21AG081681?
R21AG081681 was awarded to The General Hospital Corporation by National Institute on Aging (National Institutes of Health) on July 1, 2023.
How much is award R21AG081681 worth?
$1,566,000 has been obligated on R21AG081681.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award